The Salt That Isn't Semaglutide: Why the Form of the Drug Matters More Than the Name on the Label

The vial says "semaglutide." The active ingredient may not be. Compounding pharmacies across the country have been using chemical cousins of the drug in Ozempic and Wegovy—salt forms called semaglutide sodium and semaglutide acetate—that the FDA has explicitly flagged as different active ingredients with no established safety or efficacy record. Meanwhile, legitimate pharmaceutical science has developed an entirely different kind of "salt"—SNAC, an absorption enhancer engineered to make oral semaglutide survive the stomach—and the two concepts are getting confused in the public conversation in ways that are genuinely dangerous.

What's actually true: FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) use a specific base form of semaglutide that underwent years of clinical trials. The oral version (Rybelsus) pairs that base form with a pharmaceutical excipient called SNAC—a purpose-built absorption enhancer that is not the same chemical class as the unapproved salt forms showing up in compounded injectables.

What's misleading or unregulated: A significant portion of compounded "semaglutide" on the market has been made with semaglutide sodium or semaglutide acetate—chemically distinct molecules the FDA has stated have no lawful basis for use in compounding and have not been shown to be safe or effective. Quality testing of market samples has found impurity levels reaching 24% or higher, including formaldehyde adducts and unknown substances. Sellers routinely describe these products as containing "the same active ingredient as Ozempic," which is false.

⚕️ LyfeiQ Score: 9/10 — The gap between what the label implies and what the vial may actually contain is documented, documented dangerous, and actively exploited at scale. If you or someone you know is using compounded GLP-1 products, this distinction matters right now.

How Do "Salts" Actually Work in Pharmaceutical Chemistry—and Why Does the Form Matter?

The word "salt" in pharmaceutical science refers to an ionic form of a drug molecule created by pairing the active compound with a counterion—sodium, acetate, hydrochloride, and others—to alter its solubility, stability, or ease of manufacturing.

This is routine drug development practice. Many common medications—from sertraline hydrochloride (Zoloft) to atorvastatin calcium (Lipitor)—are sold in salt form because the salt offers better shelf stability or absorption characteristics than the free base. When a salt form of a drug is used, regulatory agencies require that it be evaluated for bioequivalence: the salt must deliver the same amount of active drug into the bloodstream, at the same rate, as the reference compound. That evaluation is the work of a formal development program, not an assumption.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a 31-amino-acid GLP-1 receptor agonist produced by Novo Nordisk through a proprietary semi-recombinant process. The approved drug products contain semaglutide base—a specific molecular form that was the subject of the SUSTAIN and STEP clinical trial programs. No clinical trials have been conducted using semaglutide sodium or semaglutide acetate as the active ingredient. The FDA has stated plainly: it does not know whether these salt forms behave the same way in the body as the base form, and it is unaware of any lawful basis for their use in compounding.

The molecular weight difference between semaglutide base and semaglutide sodium is approximately 8–15%, depending on formulation. That means a vial labeled as containing a given dose of "semaglutide" using the sodium salt delivers measurably less active drug per unit volume unless the concentration is adjusted—and multiple pharmacy testing reports have shown it often isn't. Independent testing submitted to FDA regulatory dockets has found compounded semaglutide samples with peptide-related impurities exceeding 24%, including formaldehyde adducts, dimers, and unidentified substances. Separately, samples have been found with zero measurable active ingredient, with contamination from trace metals, and with residual solvents.

The oral story is different—and worth understanding separately to avoid conflating two unrelated things.

Rybelsus, the oral tablet form of semaglutide, uses semaglutide base co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate)—a small fatty-acid derivative developed by Emisphere Technologies and licensed by Novo Nordisk. SNAC is not a drug salt in the pharmacological sense; it is a pharmaceutical excipient, a helper molecule. Its job is to create a transient protective microenvironment around the semaglutide molecule in the stomach: it raises local pH to inhibit pepsin, reduces semaglutide oligomerization, and temporarily fluidizes gastric epithelial membranes to enable transcellular absorption. Published in Nature Communications (2025), computational and experimental work confirmed this mechanism—characterizing it as permeation-enhancer-filled membrane defects that allow the peptide to pass through the gastric lining. Even with SNAC, oral bioavailability of semaglutide remains below 1%. Each Rybelsus tablet contains roughly 300 mg of SNAC alongside 7–14 mg of semaglutide—a 20:1 to 100:1 ratio, which gives a sense of how difficult oral peptide delivery is. The SNAC technology was FDA-approved in September 2019 and EMA-approved in March 2020.

The distinction: SNAC is a vetted excipient in a rigorously studied formulation. Semaglutide sodium and semaglutide acetate are chemically different active ingredients in products that have undergone no such study. One is pharmaceutical engineering. The other is an unstudied substitution marketed as though it were equivalent.

What Should You Actually Check Before You Use a Compounded GLP-1 Product?

The first thing to establish is legal status.

As of February 21, 2025, the FDA officially declared the semaglutide injection shortage resolved. The enforcement discretion periods that had temporarily permitted mass compounding ended for 503A pharmacies on April 22, 2025, and for 503B outsourcing facilities on May 22, 2025.

That means: broad compounding of semaglutide is no longer legally permitted. Narrow exceptions exist—documented allergy to an inactive ingredient in the brand-name product, or a clinically justified need for a formulation not commercially available—but "it's cheaper" does not qualify. If you are purchasing compounded semaglutide in 2025 or 2026 outside those narrow exceptions, the pharmacy producing it may not be operating within the law.

If you have a legitimate exception and are using a compounded product, here are the specific questions to ask:

• Ask directly: "Which form of semaglutide does this pharmacy use—base, sodium salt, or acetate salt?" Insist on a direct answer. Semaglutide base is the only lawful form.

• Request a Certificate of Analysis (COA) from the active pharmaceutical ingredient (API) supplier. The COA will specify the form used. If the pharmacy cannot or will not provide one, that is a significant warning sign.

• Ask: "Is this pharmacy 503A or 503B registered?" 503A pharmacies must have an individual patient-specific prescription and documented clinical need. 503B outsourcing facilities are subject to FDA inspection and current good manufacturing practice (CGMP) requirements—a meaningfully higher quality bar.

• Request third-party potency testing on the finished product. A reputable compounder should be able to show that the concentration in the vial matches what is on the label.

• Check whether the product arrived refrigerated and with appropriate cold-chain documentation. Injectable peptides require refrigeration; the FDA has received reports of compounded GLP-1 products arriving warm.

Be alert to specific marketing language. Claims that a compounded product contains "the same active ingredient as Ozempic" or is "clinically proven" are false and have been specifically cited in FDA warning letters issued in 2025. If you are currently injecting a compounded GLP-1 and do not know whether it uses the base form, ask your prescribing clinician or pharmacist to verify the API form and provide documentation. If they cannot, a conversation with a licensed physician is warranted before continuing.

What Do Regulators, Manufacturers, and the Market Actually Say?

Perspective 1: The Regulatory Record

The FDA's position on semaglutide salt forms is unambiguous and documented.

The agency's published safety information states it does not have information on whether the salt forms have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and the FDA is not aware of any lawful basis for their use in compounding. That is regulatory language for: we don't know if this is safe, and there is no legal basis for doing it.

The FDA has issued multiple adverse event alerts tied to compounded semaglutide, including hospitalizations from dosing errors where patients received five to twenty times the intended dose. A July 2024 alert specifically cited the salt form issue alongside documented overdose reports. The agency has also issued warning letters to telehealth companies and compounding pharmacies for false advertising—citing claims that products contain "the same active ingredient" as Ozempic when they may not.

Under the Drug Quality and Security Act (DQSA) of 2013, 503A pharmacies are not subject to FDA good manufacturing practice requirements, are not routinely inspected by the FDA, and are not required to submit adverse event reports to the agency. The FDA has acknowledged this means adverse events from compounded products are likely substantially underreported. This creates a structural information gap: harm from these products is occurring at an unknown rate because the reporting infrastructure is not in place.

Perspective 2: What the Manufacturing and Quality Data Shows

Novo Nordisk, the manufacturer of all FDA-approved semaglutide products, does not sell semaglutide base—in any form—to compounding pharmacies.

The API used by compounders is sourced from third-party bulk API manufacturers, primarily in China and India, through supply chains that vary significantly in their quality controls. Independent laboratory testing submitted to FDA regulatory dockets in 2024 and 2025 found that compounded semaglutide samples showed impurity profiles substantially different from pharmaceutical-grade material. One sample showed more than 24% peptide-related impurities, including 19.29% formaldehyde adducts, dimers, and other unknown substances. Other samples showed trace metal contamination at levels hundreds or thousands of times the acceptable limits found in Novo Nordisk's approved product.

Formaldehyde adducts in peptide drugs are not a theoretical concern. Research published in Molecular Pharmaceutics has documented that endogenous formaldehyde can modify lysine residue pairs in peptides—the kind of structural modification that can alter how a molecule behaves in the body and potentially trigger immune responses. These are not inert impurities.

By mid-2025, compounding pharmacies had begun adding supplemental ingredients—B vitamins, citric acid variants—to argue their products were not "essentially copies" of the approved drugs, a legal distinction that determines whether compounding is permissible. The IQVIA research firm found in an October 2025 report that approximately 80% of compounded semaglutide and tirzepatide prescriptions included such supplemental ingredients. Eli Lilly issued a warning about potential impurity risks from these combination compounds, noting that interaction data simply doesn't exist for most of these combinations.

Perspective 3: How These Products Are Being Marketed

The most pervasive marketing claim in the compounded GLP-1 space—that compounded products contain "the same active ingredient as Ozempic"—has been directly addressed by the FDA and found false.

Sellers frequently advertise these products as "clinically proven," which they are not. The clinical evidence for semaglutide is for the base form, in FDA-approved dosages, manufactured under pharmaceutical-grade conditions. No clinical trials have been conducted on semaglutide sodium, semaglutide acetate, or any compounded formulation.

Popular creators and telehealth platforms have described the price difference—compounded products at $150–$300 per month versus brand-name products at over $1,000—as the primary argument for their use, which is a legitimate access concern. But access to an unapproved product of uncertain composition is not the same as access to the medication that was clinically proven. The framing elides a meaningful distinction.

A responsible counter-example exists. Telehealth platforms such as Ro, which partnered with Eli Lilly on approved tirzepatide access, and Hims & Hers, which reached an agreement with Novo Nordisk in 2025, have moved toward facilitating access to FDA-approved products rather than compounded alternatives. These arrangements typically involve manufacturer savings programs that reduce out-of-pocket cost substantially for eligible patients.

Where Does the Label Stop Telling the Truth?

The three perspectives converge on a single point: the label on a compounded "semaglutide" product may accurately describe what the compounder intended to put in the vial, while failing to convey that the active ingredient differs from what was used in clinical trials, that impurities may be present at levels that would cause a pharmaceutical product to fail its release testing, and that the legal basis for the product's existence may have ended.

The SNAC confusion compounds this. Because SNAC is described as a "sodium salt derivative" in some technical descriptions, and because semaglutide sodium is also a sodium-containing compound, the two are easy to conflate—and some marketing does conflate them, presenting SNAC-related language as a way to describe compounded injectable salt forms as though they had the same scientific backing. They don't. SNAC is a proprietary, FDA-approved excipient with a thoroughly described mechanism. Semaglutide sodium as an injectable active ingredient has no approved clinical history.

The hydration and dietary electrolyte angle—sometimes raised in discussions of GLP-1 therapy, since semaglutide-driven nausea can reduce oral intake—is also separate from the salt form issue. Dietary sodium from hydration or food is absorbed through entirely different mechanisms than an injected pharmaceutical active ingredient. The word "salt" is doing very different work in these contexts, and the overlap in terminology has been exploited to muddy the regulatory and safety picture.

What Comes Next

The FDA's regulatory posture is tightening.

As of April 2026, the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list on the grounds that there is no clinical need for outsourcing facilities to compound these drugs while FDA-approved versions are available. If finalized, this would close the last major structural pathway for large-scale GLP-1 compounding. Litigation from the Outsourcing Facilities Association remains ongoing in the 5th Circuit, and the outcome will shape enforcement going forward.

On the science side, the field of oral peptide delivery is advancing. Transient Permeation Enhancer (TPE) technology, which temporarily opens tight junctions between intestinal epithelial cells to allow paracellular absorption, has reached Phase 3 clinical trials for oral octreotide. If validated, approaches like these could expand the range of biologics deliverable by mouth—reducing the injection burden that makes compounded alternatives attractive in the first place.

The broader enforcement question is whether the FDA's warning letter campaign, manufacturer lawsuits, and proposed rulemaking will be sufficient to address a market that, per IQVIA data, continued growing in prescription volume even after the shortage ended and the legal basis for compounding was eliminated.

What Is the GLP-1 Salt Form Gap's LyfeiQ?

Credibility Rating: 9/10 — The regulatory record is documented and specific. FDA warning letters, adverse event data, and independent impurity testing all point in the same direction. The gap is real, not speculative.

• Perception Gap: 9/10 — Most consumers have no idea the salt form of the active ingredient matters, or that "semaglutide" on a vial label may refer to a different molecule than the one in Ozempic.

• Real-World Risk: 9/10 — The gap translates directly into documented adverse events, hospitalizations, and unknown long-term effects from unstudied active ingredients and significant impurity loads.

• How Often It's Exploited: 8/10 — Widespread, ongoing, and actively marketed despite FDA warning letters. Prescription volumes for compounded GLP-1s increased after the shortage ended.

Risk-Benefit Ratio: Unfavorable — for a patient who has access to the FDA-approved product.

Medical/Regulatory Consensus: The FDA has determined semaglutide sodium and semaglutide acetate are different active ingredients from semaglutide base, with no lawful basis for use in compounding and no established safety or efficacy data. The shortage-era basis for compounded products has ended.

👉 Who should care most: Anyone who has been prescribed or is considering a compounded GLP-1 injectable product, particularly through a telehealth platform or cash-pay clinic. Clinicians and pharmacists who prescribe or dispense these products.

👉 Who can safely ignore this: Patients using FDA-approved Ozempic, Wegovy, or Rybelsus obtained through a licensed pharmacy with a valid prescription. The salt form issue does not apply to these products.

⚕️ LyfeiQ Score: 9/10 — A compounded injectable labeled as "semaglutide" may contain a chemically different active ingredient, with no clinical safety or efficacy data and documented impurity problems. If you are using a compounded GLP-1 product, confirm the API form with documentation from your pharmacy before your next dose.

Related: The Hidden Dangers of Compounded Weight Loss Drugs: Why Your Affordable Ozempic Might Be Playing Russian Roulette

1. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
2. FDA. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. July 26, 2024. fda.gov
3. FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. February 2025. fda.gov
4. FDA. Warning Letter: JulyMD. September 9, 2025. fda.gov
5. Birkofer T, et al. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical Diabetes. 2024;42(1):74–81. diabetesjournals.org
6. Visscher S, et al. Permeation Enhancer-Induced Membrane Defects Assist the Oral Absorption of Peptide Drugs. Nature Communications. 2025. nature.com
7. Novo Nordisk. Comment Regarding Compounded Semaglutide Impurity Data. Submitted to FDA Docket FDA-2015-N-0030. April 22, 2025. regulations.gov
8. Vivek MSS, Chandaliya KC. Semaglutide Salt versus Base Formulations: A Regulatory and Pharmacovigilance Imperative. International Journal of Basic & Clinical Pharmacology. 2026;15(3):594–595. doi.org
9. Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. June 2026. pharmacytimes.com
10. Michiels TJM, et al. Novel Formaldehyde-Induced Modifications of Lysine Residue Pairs in Peptides and Proteins. Molecular Pharmaceutics. 2020;17(11):4375–4380. doi.org

Disclaimer: This content includes personal opinions and interpretations based on available sources and should not replace medical advice. This content includes interpretation of available research and should not replace medical advice. Although the data found in this blog and infographic has been produced and processed from sources believed to be reliable, no warranty expressed or implied can be made regarding the accuracy, completeness, legality or reliability of any such information. This disclaimer applies to any uses of the information whether isolated or aggregate uses thereof.